US20070031957A1 - Extraction and purification of phosphodiesterase - Google Patents
Extraction and purification of phosphodiesterase Download PDFInfo
- Publication number
- US20070031957A1 US20070031957A1 US11/544,908 US54490806A US2007031957A1 US 20070031957 A1 US20070031957 A1 US 20070031957A1 US 54490806 A US54490806 A US 54490806A US 2007031957 A1 US2007031957 A1 US 2007031957A1
- Authority
- US
- United States
- Prior art keywords
- extract
- pde
- concentration
- magnesium
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
Definitions
- Phosphodiesterase 1 (orthophosphoric diester phosphohydrolase, EC 3.1.4.1; herein “PDE-1”) is an enzyme that catalyses the hydrolysis of a phosphodiester bond at the 3′ hydroxyl end of ribopolynucleotide to yield a 5′ ribonucleotide.
- PDE-1 is particularly important to food and pharmaceutical industries because the 5′ ribonucleotides produced by PDE-1—mediated cleavage of yeast RNA are useful as flavour enhancers.
- Barley cells or rootlets are used in the food industry as a source of PDE-1.
- the invention seeks to at least minimise one or more of the above identified problems or limitations and/or to provide an improved process for purification of PDE-1.
- the invention provides a process for purifying PDE-1 from a cell.
- the process includes the step of heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract.
- concentration of divalent cation is at least about 20 mM.
- the invention provides a process for purifying PDE-1 from a barley cell.
- the process includes the following steps:
- the concentration of calcium in the solution is at least about 20 mM.
- concentration of magnesium in the solution is at least about 20 mM.
- the invention provides a process for purifying PDE-1 from barley cell.
- the process includes the following steps:
- the concentration of calcium in the solution is at least about 20 mM.
- concentration of magnesium in the solution is at least about 20 mM.
- the cell is a barley cell, such as a cell derived from a barley rootlet.
- the invention provides PDE-1 produced by the process of the invention.
- the invention provides a cell including PDE-1 produced by the process of the invention.
- the invention provides a process for producing a ribonucleotide.
- the process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the 5′ ribonucleotide.
- the invention provides a ribonucleotide produced by the above described process.
- heat treatment of an extract of a barley cell or rootlet in a solution comprising at least one divalent cation permits the specific activity of the extract to be increased.
- the specific activity of a heat treated extract of a barley rootlet formed from a solution comprising calcium and magnesium was observed to increase 2.6 fold over a non heat treated sample (312.6 ⁇ 10 ⁇ 3 compared with 122 ⁇ 10 ⁇ 3 ⁇ moles/min/mL).
- a heat treated extract containing calcium and magnesium was observed to have an improved specific activity (78 ⁇ 10 ⁇ 3 ⁇ moles/min/mL) compared with a heat treated extract containing no calcium and magnesium (46 ⁇ 10 ⁇ 3 ⁇ moles/min/mL).
- the at least one divalent cation in the solution may be magnesium and/or calcium.
- the solution may contain MgCl 2 and/or CaCl 2 .
- the magnesium and calcium ions may be included in the extract in an amount to permit control of the denaturation of PDE-1 when the extract is heated.
- magnesium and calcium are included in the extract in an amount to at least limit the denaturation of PDE-1 when the extract is heated.
- the concentration of calcium may be less than 100 mM, but at least about 20 mM and the concentration of magnesium may be less than 100 mM, but at least about 20 mM.
- a concentration of calcium and magnesium in a range between at least about 20 to 50 mM is particularly useful as further down stream processing of the extract for further purification, such as anion exchange chromatography, may require removal of calcium and magnesium. Accordingly a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful. Further, a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful. Also, a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful. Still further a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful. A concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- phosphomonoesterase is a major constituent of an extract of a barley rootlet.
- the extract is typically heated to a temperature that permits denaturation of phosphomonoesterase, or otherwise, destruction of phosphomonoesterase activity in the extract. As described herein, temperatures less than 80° C. are suitable for this purpose.
- the inventor has also found that the purification of PDE-1 from a barley cell extract can be improved by extracting a barley cell homogenate at 4° C. in a solution including magnesium and calcium. Specifically, as described herein, the specific activity of an extract comprising calcium and magnesium after maintenance at 4° C. was found to be 92 ⁇ 10 3 ⁇ moles/min/mL as compared with the activity of an extract maintained at 4° C. in the absence of calcium and magnesium (75 ⁇ 10 3 ⁇ moles/min/mL).
- a process for purifying PDE-1 from a barley cell includes the following steps:
- a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful.
- a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful.
- a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful.
- a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful.
- a concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract.
- the extract may be maintained at less than 10° C. for less than 5 days.
- the extract may be maintained between 0 to about 4° C. for between about 1 to 48 hours.
- PDE-1 can be purified to virtual homogeneity from a barley cell extract by a process including the following steps:
- a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful.
- a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful.
- a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful.
- a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful.
- a concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- PDE-1 can be further purified from a heat treated barley cell extract by anion exchange chromatography. Accordingly, typically, in step (c), anion exchange chromatography is utilised to purify PDE-1 from the heated extract.
- the inventor has found that calcium and magnesium ions tend to limit binding of PDE-1 during anion exchange chromatography. Accordingly, typically the extract is desalted before anion exchange chromatography.
- One way of desalting to remove magnesium and calcium ions is by ultrafiltration.
- a preparative de-salting column such as a Hi trap 26/10 desalting column can be used. It is particularly advantageous to remove substantially all of the calcium and magnesium from the extract prior to anion exchange chromatography for the purpose of maximising the yield of PDE-1 purified from the anion exchange column.
- the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract.
- the extract of the barley cell is typically produced by homogenising barley rootlets in an appropriate buffer.
- a blender such as a Waring blender.
- the extract may be produced by milling barley rootlets in an appropriate buffer.
- the solution into which the PDE-1 from the cell is released to form an extract is typically a buffer for controlling pH.
- Solutions prepared from Trisma base are examples of such a solution.
- a solution having a concentration of no more than about 100 mM Tris is suitable, however a solution having a concentration between about 20 to 50 mM Tris, for example, 25 mM Tris is particularly advantageous because as described herein, this concentration of Tris is compatible with, and permits separation of PDE-1 on, an anion exchange column.
- processes of the invention are useful for purifying PDE-1 from cells other than barley cells. Further, it will be understood that processes of the invention are useful for isolating barley PDE-1 from cells that contain a recombinant nucleic acid molecule that encodes barley PDE-1. Examples of such cells include bacterial cells and yeast cells.
- the invention provides a process for producing a ribonucleotide.
- the process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the ribonucleotide.
- the polyribonucleotide is derived from yeast RNA, such as yeast ribosomal RNA.
- Germinating barley seeds were obtained from Barrett Burston Malting, (Thornleigh, NSW, Australia). Thymidine 5′ monophosphate p-nitrophenyl ester, Trisma base, MgCl 2 , CaCl 2 , p-nitrophenyl-phosphate, Baker's yeast RNA, bovine serum albumin, guanosine 5′-monophosphate, potassium dihydrogen orthophosphate were all supplied by Sigma Aldrich (Castle Hill, NSW Australia).
- Yeast rRNA was prepared as a 3 mg/mL standard solution in RNAse free Milli Q water (pH 7.0) in a clean room environment and immediately frozen to minus 80° C. and stored until required.
- Guanosine 5′-monophosphate was prepared as a 1% (w/v) stock by dissolving in Milli Q water and storing at ⁇ 20° C. Working solutions were prepared by diluting the stock solution to 0.01% (w/v).
- the buffer used for FPLC was 25 mM Tris HCl (pH 8.9).
- the eluent buffer included 1 M NaCl.
- solvent (A) was 0.02M potassium dihydrogen orthophosphate (pH 6.5) solution while solvent (B) was a 40% methanol (HPLC grade) and 60% Milli Q water mixture (pH 6.5).
- An Amersham Pharmacia AKAT gradient processing FPLC system complete with a 900 model monitor, lamp and detector (set at 280 nm), 920 model pump and Frac 950 fraction collector interfaced to a Compaq Deskpro Pentium III computer supporting Unicorn analytical software was used for all protein purification.
- the columns used included a Hi Trap 26/10 desalting column connected to a Super loop 50 (to facilitate larger injection volumes), a 16/10 Hi-Load Q anion exchange column with a final purification undertaken on a Mono Q HR 5/5 column.
- the HPLC system used for the analysis of 5′ nucleotides was a Shimadzu Liquid Chromatography unit, consisting of a Shimadzu pump (model LC-10Ai) with an on-line degassing unit, SCL-10A system controller, SPD-M10A diode array detector and a column oven (set at 30° C.), the system was controlled by a Dell Pentium III computer operating a Shimadzu class VP (version 5.03) analytical software program.
- the column used for the analysis of 5′ ribonucleotides was an Activon Goldpak HPLC column (250 mm ⁇ 4.6 mm, 5 mm particle size and 10 nm pore size). Peak heights were determined from chromatograms recorded at both 245 nm and 280 nm.
- a Pharmacia LKB UV-Visible spectrophotometer was also used to measure enzyme activity and was set at 410 nm with an aligned temperature control cell all controlled by a HP Pentium II computer operating a Biochrome 4060 enzyme kinetics software program.
- a solution of 10 mg/100 mL of p-nitrophenol was prepared in 50 mM Tris HCl (pH 8.9) to yield a concentration of 0.719 ⁇ moles/ml of p-nitrophenol.
- Dilutions were prepared in 50 mM Tris HCl (pH8.9) and read as a 4.1 mL sample size at 410 nm to directly correlate with the enzyme activity absorbances at each purification step.
- Protein was determined using the BioRad micro assay procedure derived from the original method of Bradford utilising a standard curve produced for bovine serum albumin. Each analysis was conducted in duplicate requiring incubation at room temperature for 10 minutes with the absorbance measured at 595 nm. Standards were prepared in the range of 0.2 to 1.4 mg/mL of protein.
- the assay solution consisted of 0.1 mL of purified PDE-1, 2.0 mL of 50 mM Tris HCl (pH 8.9), 1 mL of 1 mM thymidine 5′ monophosphate p-nitrophenyl ester in 50 mM Tris HCl (pH 8.9) and 1 mL of a 50 mM MgCl 2 in 50 mM Tris HCl (pH 8.9).
- the reaction mixture was incubated at 37° C. for 30 minutes with the optical density of enzymatically produced p-nitrophenol measured at 410 nm each minute to determine the PDE-1 reaction kinetics.
- the activity was determined by extrapolation against a standard curve with 1 unit of activity defined as the micromoles of p-nitrophenol produced from p-nitrophenyl ester per minute per mL of purified PDE-1. Specific activity was defined as the activity per milligram of purified PDE-1.
- the HPLC column was equilibrated with 100% buffer A for 30 minutes at a flow rate of 1 ml ⁇ min ensuring the pressure remained below 180 Kpa.
- the ratio of solvent B in the elution system was increased linearly over 18 minutes to 40% then increased to 100% over the next 2 minutes and held for a further 2 minutes to flush any remaining strongly bound compounds.
- the system was automatically returned to its starting conditions over the following 8 minutes and stabilised on buffer A for a further 30 minutes before the next injection.
- the total analysis time was 60 minutes with elution performed at 30° C. oven temperature.
- 10 g of fresh barley rootlets were obtained from seeds that had been germinating for 5 days including a 2 day steep in 5 mg/kg gibberellic acid to facilitate enzyme extraction.
- the rootlets were dispersed in 100 mL 25 mM Tris-HCl (pH 7.5) containing 50 mM MgCl 2 and 50 mM CaCl 2 . This mixture was homogenised in a Waring blender at high speed for 1 minute and maintained at 4° C. for 24 hours to facilitate solubilisation of PDE-1.
- the insoluble material was removed from the extract by filtering through double cheese cloth.
- the filtrate was then centrifuged at 15,000 rpm for 30 minutes at 4° C. to remove solids and the supernatant was passed through a 0.45 ⁇ M filter and stored at 4° C. in a sterile container with 0.01% sodium azide. This process formed the crude PDE-1 extract.
- the activity and specific activity of the crude PDE-1 extract was then determined according to Examples 2 to 4 above.
- the first stage of the purification process involved the removal of heat labile enzymes (primarily Acid Phosphatase [Phosphomonoesterase (PME)] EC 3.1.3.2) and inhibitory proteins from the crude PDE-1 extract with the aim of reducing any loss of activity or damage to the structure of PDE-1.
- heat labile enzymes primarily Acid Phosphatase [Phosphomonoesterase (PME)] EC 3.1.3.2
- PME Acid Phosphatase
- the activity and specific activity of the heat treated PDE-1 extract was then determined according to Examples 2 to 4 above.
- Ion exchange chromatography was then undertaken.
- a 100 mL sample of the extract was injected into a Super loop 50 column and desalted by FPLC on a Hi Trap 26/10 desalting column at a flow rate of 7.0 mL per minute, to remove magnesium and calcium.
- the desalted fractions were then pooled and reloaded onto the Super loop column and passed through a Hi load 16/10 anion exchange column at 3.0 mL per minute to initially fractionate PDE-1.
- the isolated fraction was again desalted to remove the 1M NaCl elution buffer and was then purified by passing the fraction through the Mono Q HR 5/5 column at 1.5 mL per minute.
- a single peak was obtained and analysed for activity and specific activity according to Examples 2 to 4 above.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Enzymes And Modification Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Extraction Or Liquid Replacement (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least on divalent cation, to increase the specific activity of PDE-1 in the extract.
Description
- This application is a continuation of U.S. application Ser. No. 11/146,902, filed Jun. 6, 2005, which is a continuation-in-part of U.S. application Ser. No. 10/733,857, filed Dec. 11, 2003, now U.S. Pat. No. 6,982,158 B2, both of which are incorporated herein by reference.
- Phosphodiesterase 1 (orthophosphoric diester phosphohydrolase, EC 3.1.4.1; herein “PDE-1”) is an enzyme that catalyses the hydrolysis of a phosphodiester bond at the 3′ hydroxyl end of ribopolynucleotide to yield a 5′ ribonucleotide.
- PDE-1 is particularly important to food and pharmaceutical industries because the 5′ ribonucleotides produced by PDE-1—mediated cleavage of yeast RNA are useful as flavour enhancers.
- Barley cells or rootlets are used in the food industry as a source of PDE-1.
- The processes for purification of PDE-1 from barley rootlets tend to be difficult to operate on a commercial scale, in terms of requiring sophisticated extraction and separation techniques, multiple steps and expensive reagents and equipment. Some processes are characterised by an unacceptable loss or wastage of PDE-1. Other processes tend to produce a final product that has a sub-optimal specific activity.
- In view of the above, there is a need for improved processes for purification of PDE-1.
- This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
- The invention seeks to at least minimise one or more of the above identified problems or limitations and/or to provide an improved process for purification of PDE-1.
- In one aspect, the invention provides a process for purifying PDE-1 from a cell. The process includes the step of heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract. Typically the concentration of divalent cation is at least about 20 mM.
- In another aspect, the invention provides a process for purifying PDE-1 from a barley cell. The process includes the following steps:
- (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; and
- (b) heating the extract to increase the specific activity of PDE-1 in the extract.
- Typically the concentration of calcium in the solution is at least about 20 mM. Typically the concentration of magnesium in the solution is at least about 20 mM.
- In another aspect, the invention provides a process for purifying PDE-1 from barley cell. The process includes the following steps:
- (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract;
- (b) heating the extract to increase the specific activity of PDE-1 in the extract; and
- (c) utilising anion exchange chromatography to purify PDE-1 from the heated extract.
- Typically the concentration of calcium in the solution is at least about 20 mM. Typically the concentration of magnesium in the solution is at least about 20 mM.
- Typically the cell is a barley cell, such as a cell derived from a barley rootlet.
- In another aspect, the invention provides PDE-1 produced by the process of the invention.
- In another aspect, the invention provides a cell including PDE-1 produced by the process of the invention.
- In another aspect, the invention provides a process for producing a ribonucleotide. The process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the 5′ ribonucleotide.
- In another aspect, the invention provides a ribonucleotide produced by the above described process.
- As described herein, the inventor has found that heat treatment of an extract of a barley cell or rootlet in a solution comprising at least one divalent cation permits the specific activity of the extract to be increased. For example, the specific activity of a heat treated extract of a barley rootlet formed from a solution comprising calcium and magnesium was observed to increase 2.6 fold over a non heat treated sample (312.6×10−3 compared with 122×10−3 μmoles/min/mL). Further, a heat treated extract containing calcium and magnesium was observed to have an improved specific activity (78×10−3 μmoles/min/mL) compared with a heat treated extract containing no calcium and magnesium (46×10−3 μmoles/min/mL).
- This is a significant finding because it permits heat treatment, a purification step that is relatively simple to operate on a commercial scale, to be implemented with minimal loss of activity of PDE-1.
- It is believed that the specific activity of the extract is increased because the divalent cation protects PDE-1 from denaturation at temperatures at which other proteins in the extract, including phosphomonoesterase, are degraded.
- Typically, the at least one divalent cation in the solution may be magnesium and/or calcium. For example, the solution may contain MgCl2 and/or CaCl2.
- The magnesium and calcium ions may be included in the extract in an amount to permit control of the denaturation of PDE-1 when the extract is heated. Typically, magnesium and calcium are included in the extract in an amount to at least limit the denaturation of PDE-1 when the extract is heated. For example, the concentration of calcium may be less than 100 mM, but at least about 20 mM and the concentration of magnesium may be less than 100 mM, but at least about 20 mM.
- A concentration of calcium and magnesium in a range between at least about 20 to 50 mM is particularly useful as further down stream processing of the extract for further purification, such as anion exchange chromatography, may require removal of calcium and magnesium. Accordingly a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful. Further, a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful. Also, a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful. Still further a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful. A concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- It is believed that phosphomonoesterase is a major constituent of an extract of a barley rootlet. Thus, the extract is typically heated to a temperature that permits denaturation of phosphomonoesterase, or otherwise, destruction of phosphomonoesterase activity in the extract. As described herein, temperatures less than 80° C. are suitable for this purpose.
- It is particularly advantageous to heat the extract to between about 45 and 75° C. because at temperatures approaching 70° C. and above, PDE-1 activity may be lost. Accordingly, a temperature of about 60° C. is particularly useful.
- The inventor has also found that the purification of PDE-1 from a barley cell extract can be improved by extracting a barley cell homogenate at 4° C. in a solution including magnesium and calcium. Specifically, as described herein, the specific activity of an extract comprising calcium and magnesium after maintenance at 4° C. was found to be 92×103 μmoles/min/mL as compared with the activity of an extract maintained at 4° C. in the absence of calcium and magnesium (75×103 μmoles/min/mL).
- It is believed that maintenance of such an extract at 4° C. is important because it permits PDE-1 to disassociate from solids in the extract, and accordingly, to solubilise into the liquid phase of the extract, prior to further processing of the extract, such as a heat treatment step or a chromatographic separation step. The calcium and magnesium are believed to be important for limiting hydrolysis of the enzyme during the maintenance of the extract at 4° C.
- Thus in accordance with the invention, a process for purifying PDE-1 from a barley cell includes the following steps:
- (a) releasing PDE-1 from the cell into a solution including at least about 20 mM calcium and at least about 20 mM magnesium to form an extract; and
- (b) heating the extract to increase the specific activity of PDE-1 in the extract.
- In this embodiment, a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful. Also, a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful. Further, a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful. Still further a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful. A concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- Typically, the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract.
- The extract may be maintained at less than 10° C. for less than 5 days. For example, the extract may be maintained between 0 to about 4° C. for between about 1 to 48 hours.
- It is particularly advantageous to maintain the extract for 24 hours at 4° C. as this improves the speed of purification protocols that comprise further purification steps.
- The inventor has further found that PDE-1 can be purified to virtual homogeneity from a barley cell extract by a process including the following steps:
- (a) releasing PDE-1 from the cell into a solution including at least about 20 mM calcium and at least about 20 mM magnesium to form an extract;
- (b) heating the extract to increase the specific activity of PDE-1 in the extract; and
- (c) utilising chromatography to purify PDE-1 from the heated extract.
- In this embodiment, a concentration of calcium ions of about 25 mM and a concentration of magnesium ions of about 25 mM is particularly useful. Also, a concentration of calcium ions of about 30 mM and a concentration of magnesium ions of about 30 mM is particularly useful. Further, a concentration of calcium ions of about 35 mM and a concentration of magnesium ions of about 35 mM is particularly useful. Still further a concentration of calcium ions of about 40 mM and a concentration of magnesium ions of about 40 mM is particularly useful. A concentration of calcium ions of about 45 mM and a concentration of magnesium ions of about 45 mM is also particularly useful.
- As described herein, PDE-1 can be further purified from a heat treated barley cell extract by anion exchange chromatography. Accordingly, typically, in step (c), anion exchange chromatography is utilised to purify PDE-1 from the heated extract.
- The inventor has found that calcium and magnesium ions tend to limit binding of PDE-1 during anion exchange chromatography. Accordingly, typically the extract is desalted before anion exchange chromatography. One way of desalting to remove magnesium and calcium ions is by ultrafiltration. Alternatively, a preparative de-salting column, such as a Hi trap 26/10 desalting column can be used. It is particularly advantageous to remove substantially all of the calcium and magnesium from the extract prior to anion exchange chromatography for the purpose of maximising the yield of PDE-1 purified from the anion exchange column.
- Typically, the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract.
- In the processes of the invention described above, the extract of the barley cell is typically produced by homogenising barley rootlets in an appropriate buffer. One way of homogenizing rootlets is by use of a blender, such as a Waring blender. Alternatively, the extract may be produced by milling barley rootlets in an appropriate buffer.
- The solution into which the PDE-1 from the cell is released to form an extract is typically a buffer for controlling pH. Solutions prepared from Trisma base are examples of such a solution. A solution having a concentration of no more than about 100 mM Tris is suitable, however a solution having a concentration between about 20 to 50 mM Tris, for example, 25 mM Tris is particularly advantageous because as described herein, this concentration of Tris is compatible with, and permits separation of PDE-1 on, an anion exchange column.
- It will be understood that the processes of the invention are useful for purifying PDE-1 from cells other than barley cells. Further, it will be understood that processes of the invention are useful for isolating barley PDE-1 from cells that contain a recombinant nucleic acid molecule that encodes barley PDE-1. Examples of such cells include bacterial cells and yeast cells.
- In another aspect, the invention provides a process for producing a ribonucleotide. The process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the ribonucleotide. Preferably the polyribonucleotide is derived from yeast RNA, such as yeast ribosomal RNA.
- Germinating barley seeds (Schooner variety) were obtained from Barrett Burston Malting, (Thornleigh, NSW, Australia). Thymidine 5′ monophosphate p-nitrophenyl ester, Trisma base, MgCl2, CaCl2, p-nitrophenyl-phosphate, Baker's yeast RNA, bovine serum albumin, guanosine 5′-monophosphate, potassium dihydrogen orthophosphate were all supplied by Sigma Aldrich (Castle Hill, NSW Australia).
- Yeast rRNA was prepared as a 3 mg/mL standard solution in RNAse free Milli Q water (pH 7.0) in a clean room environment and immediately frozen to minus 80° C. and stored until required.
- Guanosine 5′-monophosphate was prepared as a 1% (w/v) stock by dissolving in Milli Q water and storing at −20° C. Working solutions were prepared by diluting the stock solution to 0.01% (w/v).
- The buffer used for FPLC was 25 mM Tris HCl (pH 8.9). The eluent buffer included 1 M NaCl.
- For the HPLC analysis, solvent (A) was 0.02M potassium dihydrogen orthophosphate (pH 6.5) solution while solvent (B) was a 40% methanol (HPLC grade) and 60% Milli Q water mixture (pH 6.5).
- All solvents and buffers were degassed and filtered prior to use by passing each solution through a Millipore membrane filter, pore size 0.45 μm under vacuum for 5 minutes.
- An Amersham Pharmacia AKAT gradient processing FPLC system complete with a 900 model monitor, lamp and detector (set at 280 nm), 920 model pump and Frac 950 fraction collector interfaced to a Compaq Deskpro Pentium III computer supporting Unicorn analytical software was used for all protein purification. The columns used included a Hi Trap 26/10 desalting column connected to a Super loop 50 (to facilitate larger injection volumes), a 16/10 Hi-Load Q anion exchange column with a final purification undertaken on a Mono Q HR 5/5 column.
- The HPLC system used for the analysis of 5′ nucleotides was a Shimadzu Liquid Chromatography unit, consisting of a Shimadzu pump (model LC-10Ai) with an on-line degassing unit, SCL-10A system controller, SPD-M10A diode array detector and a column oven (set at 30° C.), the system was controlled by a Dell Pentium III computer operating a Shimadzu class VP (version 5.03) analytical software program. The column used for the analysis of 5′ ribonucleotides was an Activon Goldpak HPLC column (250 mm×4.6 mm, 5 mm particle size and 10 nm pore size). Peak heights were determined from chromatograms recorded at both 245 nm and 280 nm.
- A Pharmacia LKB UV-Visible spectrophotometer was also used to measure enzyme activity and was set at 410 nm with an aligned temperature control cell all controlled by a HP Pentium II computer operating a Biochrome 4060 enzyme kinetics software program.
- A solution of 10 mg/100 mL of p-nitrophenol was prepared in 50 mM Tris HCl (pH 8.9) to yield a concentration of 0.719 μmoles/ml of p-nitrophenol. Dilutions were prepared in 50 mM Tris HCl (pH8.9) and read as a 4.1 mL sample size at 410 nm to directly correlate with the enzyme activity absorbances at each purification step.
- Protein was determined using the BioRad micro assay procedure derived from the original method of Bradford utilising a standard curve produced for bovine serum albumin. Each analysis was conducted in duplicate requiring incubation at room temperature for 10 minutes with the absorbance measured at 595 nm. Standards were prepared in the range of 0.2 to 1.4 mg/mL of protein.
- The assay solution consisted of 0.1 mL of purified PDE-1, 2.0 mL of 50 mM Tris HCl (pH 8.9), 1 mL of 1 mM thymidine 5′ monophosphate p-nitrophenyl ester in 50 mM Tris HCl (pH 8.9) and 1 mL of a 50 mM MgCl2 in 50 mM Tris HCl (pH 8.9). The reaction mixture was incubated at 37° C. for 30 minutes with the optical density of enzymatically produced p-nitrophenol measured at 410 nm each minute to determine the PDE-1 reaction kinetics.
- The activity was determined by extrapolation against a standard curve with 1 unit of activity defined as the micromoles of p-nitrophenol produced from p-nitrophenyl ester per minute per mL of purified PDE-1. Specific activity was defined as the activity per milligram of purified PDE-1.
- Confirmation of enzyme activity was undertaken by reaction of the purified enzyme with 3 mg/mL Baker's yeast RNA and measuring the 5′ribonucleotide products by reverse phase HPLC.
- The HPLC column was equilibrated with 100% buffer A for 30 minutes at a flow rate of 1 ml·min ensuring the pressure remained below 180 Kpa. The ratio of solvent B in the elution system was increased linearly over 18 minutes to 40% then increased to 100% over the next 2 minutes and held for a further 2 minutes to flush any remaining strongly bound compounds. The system was automatically returned to its starting conditions over the following 8 minutes and stabilised on buffer A for a further 30 minutes before the next injection. The total analysis time was 60 minutes with elution performed at 30° C. oven temperature.
- 10 g of fresh barley rootlets were obtained from seeds that had been germinating for 5 days including a 2 day steep in 5 mg/kg gibberellic acid to facilitate enzyme extraction. The rootlets were dispersed in 100 mL 25 mM Tris-HCl (pH 7.5) containing 50 mM MgCl2 and 50 mM CaCl2. This mixture was homogenised in a Waring blender at high speed for 1 minute and maintained at 4° C. for 24 hours to facilitate solubilisation of PDE-1.
- The insoluble material was removed from the extract by filtering through double cheese cloth. The filtrate was then centrifuged at 15,000 rpm for 30 minutes at 4° C. to remove solids and the supernatant was passed through a 0.45 μM filter and stored at 4° C. in a sterile container with 0.01% sodium azide. This process formed the crude PDE-1 extract.
- The activity and specific activity of the crude PDE-1 extract was then determined according to Examples 2 to 4 above.
- The first stage of the purification process involved the removal of heat labile enzymes (primarily Acid Phosphatase [Phosphomonoesterase (PME)] EC 3.1.3.2) and inhibitory proteins from the crude PDE-1 extract with the aim of reducing any loss of activity or damage to the structure of PDE-1. To inactivate PME, the crude extract was heated in a water bath to 60° C. and maintained at that temperature for 1 hour. The extract was then cooled to room temperature and the pH adjusted to 8.9. The extract was then filtered through a 0.45 μm filter.
- The activity and specific activity of the heat treated PDE-1 extract was then determined according to Examples 2 to 4 above.
- Ion exchange chromatography was then undertaken. A 100 mL sample of the extract was injected into a Super loop 50 column and desalted by FPLC on a Hi Trap 26/10 desalting column at a flow rate of 7.0 mL per minute, to remove magnesium and calcium. The desalted fractions were then pooled and reloaded onto the Super loop column and passed through a Hi load 16/10 anion exchange column at 3.0 mL per minute to initially fractionate PDE-1. The isolated fraction was again desalted to remove the 1M NaCl elution buffer and was then purified by passing the fraction through the Mono Q HR 5/5 column at 1.5 mL per minute. A single peak was obtained and analysed for activity and specific activity according to Examples 2 to 4 above.
- The results for the purification of PDE-1 are shown in Table 1.
TABLE 1 Purification Sample Activity Specific activity factor Crude extract 169 122 1 Heat treatment 156.3 312.6 2.6 Anion 267.5 1407.9 11.5 exchange
Activity: ×10−3 μmoles/min/mL
Specific activity: ×10−3 μmoles/min/mL/mg
- We sought to determine whether calcium and magnesium would have an effect on stabilisation of PDE-1 in the crude extract, or otherwise, on preserving or enhancing PDE-1 activity of the crude extract, during the step of solubilising PDE-1 at 4° C. that follows the homogenisation step described in Example 6.
- To this end we maintained the homogenised extract at 4° C. in 25 mM Tris HCl (pH 8.9): (i) in the absence of calcium and magnesium; (ii) with 5 mM MgCl2 and 5 mM CaCl2; and (iii) with 50 mM MgCl2 and 50 mM CaCl2.
- We found that calcium and magnesium enhanced and indeed stabilised PDE-1. At 50 mM MgCl2 and 50 mM CaCl2, the PDE-1 activity was 22% greater than in the sample with no magnesium or calcium (92×103 μmoles/min/mL compared to 75×103 μmoles/min/mL).
- We sought to determine whether calcium and magnesium would have an effect on stabilisation of PDE-1 in the crude extract or otherwise on preserving or enhancing PDE-1 activity of the crude extract, during the step of heating PDE-1 as described in Example 7.
- To this end, we incubated the crude extract at 60° C. for 1 hour in 25 mM Tris HCl (pH 8.9): (i) in the absence of calcium and magnesium; (ii) with 5 mM MgCl2 and 5 mM CaCl2; and (iii) with 50 mM MgCl2 and 50 mM CaCl2.
- We found that after heating, the activity dropped significantly in samples without magnesium and calcium and in samples with 5 mM MgCl2 and 5 mM CaCl2 by over 40% compared with samples with 50 mM MgClμ2 and 50 mM CaCl2 (46×103 μmoles/min/mL and μ48×103 μmoles/min/mL compared with 78×103 μmoles/min/mL).
- While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.
Claims (13)
1. A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract, wherein the concentration of the divalent cation is at least about 20 mM.
2. A process according to claim 1 wherein the concentration of the divalent cation is about 20 mM to 50 mM.
3. A process according to claim 2 wherein the concentration of the divalent cation is about 25 mM.
4. A process according to claim 2 wherein the concentration of the divalent cation is about 30 mM.
5. A process according to claim 2 wherein the concentration of the divalent cation is about 35 mM.
6. A process according to claim 2 wherein the concentration of the divalent cation is about 40 mM.
7. A process according to claim 2 wherein the concentration of the divalent cation is about 45 mM.
8. A process according to claim 1 wherein the divalent cation is magnesium or calcium.
9. A process for purifying PDE-1 from a barley cell including:
releasing PDE-1 from the cell into a solution including at least about 20 mM calcium and at least about 20 mM magnesium to form an extract; and
heating the extract to increase the specific activity of PDE-1 in the extract.
10. A process according to claim 9 wherein the extract is maintained in conditions for promoting solubilization of the phosphodiesterase in the extract prior to heating the extract.
11. A process according to claim 10 wherein the extract is maintained at less than 10° C.
12. A process according to claim 11 comprising the further step of:
utilizing chromatography to purify PDE-1 from the heated extract.
13. A process according to claim 12 wherein anion exchange chromatography is utilized to purify PDE-1 from the heated extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/544,908 US20070031957A1 (en) | 2003-05-14 | 2006-10-05 | Extraction and purification of phosphodiesterase |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003902303A AU2003902303A0 (en) | 2003-05-14 | 2003-05-14 | Extracting and purifying enzymes |
AU2003902303 | 2003-05-14 | ||
US10/733,857 US6982158B2 (en) | 2003-05-14 | 2003-12-11 | Extraction and purification of phosphodiesterase 1 |
US11/146,902 US20060014263A1 (en) | 2003-05-14 | 2005-06-06 | Extraction and purification of phosphodiesterase |
US11/544,908 US20070031957A1 (en) | 2003-05-14 | 2006-10-05 | Extraction and purification of phosphodiesterase |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/146,902 Continuation US20060014263A1 (en) | 2003-05-14 | 2005-06-06 | Extraction and purification of phosphodiesterase |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070031957A1 true US20070031957A1 (en) | 2007-02-08 |
Family
ID=31501172
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/733,857 Expired - Fee Related US6982158B2 (en) | 2003-05-14 | 2003-12-11 | Extraction and purification of phosphodiesterase 1 |
US11/146,902 Abandoned US20060014263A1 (en) | 2003-05-14 | 2005-06-06 | Extraction and purification of phosphodiesterase |
US11/544,908 Abandoned US20070031957A1 (en) | 2003-05-14 | 2006-10-05 | Extraction and purification of phosphodiesterase |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/733,857 Expired - Fee Related US6982158B2 (en) | 2003-05-14 | 2003-12-11 | Extraction and purification of phosphodiesterase 1 |
US11/146,902 Abandoned US20060014263A1 (en) | 2003-05-14 | 2005-06-06 | Extraction and purification of phosphodiesterase |
Country Status (8)
Country | Link |
---|---|
US (3) | US6982158B2 (en) |
EP (1) | EP1631583B1 (en) |
JP (1) | JP2006525788A (en) |
AT (1) | ATE484519T1 (en) |
AU (1) | AU2003902303A0 (en) |
DE (1) | DE60334577D1 (en) |
DK (1) | DK1631583T3 (en) |
WO (1) | WO2004101613A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003902303A0 (en) * | 2003-05-14 | 2003-05-29 | Protech Research Pty Ltd | Extracting and purifying enzymes |
AU2011240317B2 (en) * | 2010-04-12 | 2015-07-16 | Implantica Patent Ltd. | System for treating a patient having an intestinal disorder |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3516907A (en) * | 1961-02-04 | 1970-06-23 | Waldhof Zellstoff Fab | Method for producing 5'-mononucleotides |
US4649111A (en) * | 1981-09-17 | 1987-03-10 | Hoechst Aktiengesellschaft | Process for the preparation of 5'-ribonucleotides |
US5034325A (en) * | 1988-03-25 | 1991-07-23 | Enzyme Bio-Systems, Ltd. | 5'-phosphodiesterase enzyme preparation and method for its production |
US5879916A (en) * | 1997-08-05 | 1999-03-09 | The Thailand Research Fund | Geranylgeraniol-18-hydroxylase from croton sublyratus |
US6982158B2 (en) * | 2003-05-14 | 2006-01-03 | Protech Research Pty Ltd | Extraction and purification of phosphodiesterase 1 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ228178A (en) * | 1988-03-25 | 1991-07-26 | Enzyme Bio Systems Ltd | Process for extracting an enzyme mixture of 5'-phosphodiesterase and nucleosidase |
-
2003
- 2003-05-14 AU AU2003902303A patent/AU2003902303A0/en not_active Abandoned
- 2003-12-04 DK DK03816948.8T patent/DK1631583T3/en active
- 2003-12-04 DE DE60334577T patent/DE60334577D1/en not_active Expired - Lifetime
- 2003-12-04 JP JP2004571747A patent/JP2006525788A/en active Pending
- 2003-12-04 WO PCT/AU2003/001618 patent/WO2004101613A1/en active Application Filing
- 2003-12-04 AT AT03816948T patent/ATE484519T1/en not_active IP Right Cessation
- 2003-12-04 EP EP03816948A patent/EP1631583B1/en not_active Expired - Lifetime
- 2003-12-11 US US10/733,857 patent/US6982158B2/en not_active Expired - Fee Related
-
2005
- 2005-06-06 US US11/146,902 patent/US20060014263A1/en not_active Abandoned
-
2006
- 2006-10-05 US US11/544,908 patent/US20070031957A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3516907A (en) * | 1961-02-04 | 1970-06-23 | Waldhof Zellstoff Fab | Method for producing 5'-mononucleotides |
US4649111A (en) * | 1981-09-17 | 1987-03-10 | Hoechst Aktiengesellschaft | Process for the preparation of 5'-ribonucleotides |
US5034325A (en) * | 1988-03-25 | 1991-07-23 | Enzyme Bio-Systems, Ltd. | 5'-phosphodiesterase enzyme preparation and method for its production |
US5879916A (en) * | 1997-08-05 | 1999-03-09 | The Thailand Research Fund | Geranylgeraniol-18-hydroxylase from croton sublyratus |
US6982158B2 (en) * | 2003-05-14 | 2006-01-03 | Protech Research Pty Ltd | Extraction and purification of phosphodiesterase 1 |
Also Published As
Publication number | Publication date |
---|---|
US20060014263A1 (en) | 2006-01-19 |
DK1631583T3 (en) | 2011-02-07 |
EP1631583B1 (en) | 2010-10-13 |
EP1631583A4 (en) | 2006-08-23 |
JP2006525788A (en) | 2006-11-16 |
AU2003902303A0 (en) | 2003-05-29 |
DE60334577D1 (en) | 2010-11-25 |
ATE484519T1 (en) | 2010-10-15 |
WO2004101613A1 (en) | 2004-11-25 |
EP1631583A1 (en) | 2006-03-08 |
US20040229332A1 (en) | 2004-11-18 |
US6982158B2 (en) | 2006-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soltis et al. | Isolation and characterization of two mutant forms of T4 polynucleotide kinase. | |
JPH08509605A (en) | Method for purifying collagenase | |
US20040137596A1 (en) | Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme | |
Dulaney et al. | Isolation of deoxyribonuclease II of rat liver lysosomes | |
Scawen et al. | The rapid purification of 3-hydroxybutyrate dehydrogenase and malate dehydrogenase on triazine dye affinity matrices | |
Zytko et al. | Ribonucleases of rat liver: I. Partial purification and properties | |
JPS6348515B2 (en) | ||
US20070031957A1 (en) | Extraction and purification of phosphodiesterase | |
CN109182439B (en) | Biotransformation method of rare ginsenoside Rg3 | |
Lamed et al. | Applications of immobilized adenosine triphosphate in the study of myosin | |
AU2003304117B2 (en) | Extracting and purifying enzymes | |
Ramseyer et al. | Purification of the cAMP receptor protein by affinity chromatography | |
Takeuchi et al. | Purification and characterization of hatching enzyme of Strongylocentrotus intermedius | |
US4027012A (en) | Process for the extraction of components having anticoagulant activity "in vivo" from snake venoms and products obtained | |
Hughes et al. | The isolation and characterization of a sequence-specific endonuclease from Anabaena subcylindrica. | |
George et al. | Biospecific fractionation matrices for sequence specific endonucleases | |
Ichinose et al. | Studies on chlorophyllase of Chlorella protothecoides III. Purification and catalytic properties | |
Bruton | Large-scale purification of enzymes | |
Kelley et al. | Genetic characterization of early amber mutations in the Escherichia coli polA gene and purification of the amber peptides | |
McKeon et al. | Purification and characterization of two ribonucleases from developing tomato fruit | |
Padmanabhan et al. | Enhanced leaching of product at elevated temperatures: alpha‐amylase produced by Bacillus licheniformis M27 in solid state fermentation system | |
Mulcahy et al. | Effect of accessible immobilized NAD+ concentration on the bioaffinity chromatographic behavior of NAD+-dependent dehydrogenases using the kinetic locking-on strategy | |
US20090137022A1 (en) | Extracting and purifying beta 1,4-xylanase | |
Shetty et al. | A rapid method for the isolation of ribonuclease from yeast (Saccharomyces carlsbergensis) | |
Wang et al. | Joining of yeast alanine transfer ribonucleic acid half molecules to form a whole molecule by T4 RNA ligase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |